Showing 751-760 of 9358 results for "".
- HS Pipeline Update: HS Patients Taking Nanobody Sonelokimab Hit HiSCR 75 as Early as Week 12https://practicaldermatology.com/news/hs-pipeline-update-hs-patients-taking-nanobody-sonelokimab-hit-hiscr-75-as-early-as-week-12/2461806/Nanobody Sonelokimab is looking good in patients with moderate-to-severe hidradenitis suppurativa (HS), according to topline Phase 2 results from MoonLake Immunotherapeutics. Nanobodies are antibody-derived targeted therapies. They consist of one or more domains based on the small antigen-binding …
- National Rosacea Society Offers New Seal of Acceptancehttps://practicaldermatology.com/news/national-rosacea-society-offers-new-seal-of-acceptance/2461801/The National Rosacea Society is launching a Seal of Acceptance program to identify skin care and cosmetic products that may be suitable for people with rosacea. “One of the most common requests the Society receives from rosacea patients is for information about which skin care and cosmetic pr…
- Dr. Neil Shah Named New KOL for LASEROPTEK Co. Ltd.https://practicaldermatology.com/news/dr-neil-shah-named-new-kol-for-laseroptek-co-ltd/2461797/Neil Shah, MD, is now a national key opinion leader (KOL) for LASEROPTEK's PALLAS UVB laser system for inflammatory skin conditions. LASEROPTEK's PALLAS laser system is a UVB laser that is US Food and Drug Administration (FDA) -cleared to treat inflammatory skin conditions and can be used either a…
- DFD-29 Shows No Major impact on Healthy Microbial Flora in Rosaceahttps://practicaldermatology.com/news/dfd-29-shows-no-major-impact-on-healthy-microbial-flora-in-rosacea/2461785/DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) doesn’t disrupt the microbial floral in healthy adults with papulopustular rosacea, according to data from a Phase 1 clinical trial. DFD-29 is being developed for the treatment of papulopustular rosacea by Journey Medical Corporat…
- Cutera's AviClear Scores FDA Nod as Long-Term Acne Treatmenthttps://practicaldermatology.com/news/cuteras-aviclear-scores-fda-nod-as-long-term-acne-treatment/2461784/The U.S. Food and Drug Administration (FDA) has cleared AviClear as a long-term treatment for mild to severe inflammatory acne vulgaris. Cutera’s AviClear initially received FDA clearance for treating acne in March 2022. Now, the FDA has cleared the device for the long-term treatment of acne. Th…
- Does IL-17 Play a Role in Skin Aging?https://practicaldermatology.com/news/does-il-17-play-a-role-in-skin-aging/2461770/Interleukin (IL)-17 may plays a central role in skin aging, according to research from Institute for Research in Biomedicine (IRB Barcelona) in collaboration with the National Center for Genomic Analysis (CNAG). The study, which was led by Dr. Guiomar Solanas, Dr. Salvador Aznar Benitah, both at I…
- Sun Pharma’s Ilumetri (Tildrakizumab Injection) Scores Nod For Plaque Psoriasis in Chinahttps://practicaldermatology.com/news/sun-pharmas-ilumetri-tildrakizumab-injection-scores-nod-for-plaque-psoriasis-in-china/2461753/The New Drug Application (NDA) of tildrakizumab injection under the brand name of Ilumetri has been approved by the National Medical Products Administration of the People’s Republic of China, Sun Pharma reports. Ilumetri is indicated for the treatment of adults with moderate-to-severe plaque pso…
- Sun Pharma, Philogen Enter Into an Exclusive Distribution, License, and Supply Agreement for Nidlegy in Europe, Australia, and New Zealandhttps://practicaldermatology.com/news/sun-pharma-philogen-enter-into-an-exclusive-distribution-license-and-supply-agreement-for-nidlegy-in-europe-australia-and-new-zealand/2461752/Sun Pharmaceutical Industries has entered into a licensing agreement for commercializing Philogen’s Nidlegy (Daromun) in the territories of Europe, Australia and New Zealand. Nidlegy, currently in Phase III clinical trials, is a new anti-cancer biopharmaceutical which is being developed by Philog…
- Skinvive by Juvéderm Scores FDA Nod to Improve Skin Smoothness in Cheekshttps://practicaldermatology.com/news/skinvive-by-juvederm-scores-fda-nod-to-improve-skin-smoothness-in-cheeks/2461717/The U.S. Food and Drug Administration gave its nod to Skinvive by Juvéderm to improve skin smoothness of the cheeks in adults over the age of 21. Skinvive by Juvéderm is the first and only hyaluronic acid (HA) intradermal microdroplet injection for skin smoothness available in the U.S. with result…
- U.S. FDA Grants Breakthrough Therapy Designation to Spevigo for the prevention of GPP Flareshttps://practicaldermatology.com/news/us-fda-grants-breakthrough-therapy-designation-to-spevigo-for-the-prevention-of-gpp-flares-1/2461694/The U.S. Food and Drug Administration has granted Breakthrough Therapy Designation (BTD) to Spevigo for the prevention of generalized pustular psoriasis (GPP) flares, Boehringer Ingelheim reports. This designation follows the Center for Drug Evaluation (CDE) of China National Medical Products Admi…